Coming October: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Brown University at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Brown University brings 2 presentations to SITC 2026 in Phoenix. Its program centres on the safety of immunotherapy drugs in the clinic. It covers an early trial adding alintegimod to the checkpoint drugs ipilimumab and nivolumab, and how cytokine release syndrome after bispecific antibody therapy affects how long patients stay in hospital.

Organization	SITC 2026 Attendance
Brown University Providence, RI
brown.edu Universities & research institutes A private research university.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm A phase 1b dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of alintegimod (ALIN) + ipilimumab (Ipi) followed by nivolumab (Nivo) in advanced solid tumor patients Exhibition Halls 4-6 · Poster 549 Clinical · New agents Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Cytokine Release Syndrome and Hospital Length of Stay Following Bispecific Antibody Therapy: A Single-Center Descriptive Study Exhibition Halls 4-6 · Poster 1011 Clinical

Organization

SITC 2026 Attendance

Brown University

Providence, RI

brown.edu

Universities & research institutes

A private research university.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

A phase 1b dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of alintegimod (ALIN) + ipilimumab (Ipi) followed by nivolumab (Nivo) in advanced solid tumor patients

Exhibition Halls 4-6 · Poster 549

Clinical · New agents